Back to Newsroom

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

NORWOOD, MA — (Marketwired) — 01/17/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union (“EU”) for the Company’s novel synthetic oral endocannabinoid-mimetic drug, JBT-101 (“Resunab”) for the treatment of systemic sclerosis.

Click here to read the full release